Horan Capital Advisors LLC. Buys 373 Shares of Johnson & Johnson (NYSE:JNJ)

Horan Capital Advisors LLC. boosted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 2.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 18,875 shares of the company’s stock after purchasing an additional 373 shares during the period. Johnson & Johnson comprises approximately 1.5% of Horan Capital Advisors LLC.’s portfolio, making the stock its 25th largest holding. Horan Capital Advisors LLC.’s holdings in Johnson & Johnson were worth $3,083,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC lifted its stake in Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares during the last quarter. Goodman Advisory Group LLC bought a new stake in Johnson & Johnson in the second quarter worth $39,000. Cardinal Capital Management Inc. lifted its stake in Johnson & Johnson by 333.3% in the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the last quarter. First Bank & Trust lifted its stake in Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after purchasing an additional 156 shares during the last quarter. Finally, Heritage Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at about $84,000. 67.94% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Sanford C. Bernstein decreased their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Bank of America decreased their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Citigroup boosted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Finally, Raymond James decreased their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $181.75.

Insiders Place Their Bets

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now owns 40,133 shares in the company, valued at $6,869,966.94. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of JNJ opened at $168.31 on Tuesday. The stock has a market cap of $440.04 billion, a PE ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The firm’s 50-day simple moving average is $176.07 and its two-hundred day simple moving average is $171.13.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.